Clinical trial Recruiting at 1 site Observational Ages 18 and up

Evaluating Incadronate for Breast Cancer with Bone Metastases

Official title: Real-world Study of Incadronate in Breast Cancer Patients With Metastatic Bone Disease: clinIcal Efficacy and Safety

Run by Fudan University · NCT06392217 · Data updated 2026-11-12

This study is testing if incadronate can help people with breast cancer that has spread to their bones feel better and stay safe while using the treatment.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment500 (estimated)
SponsorFudan University
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedMarch 12, 2024
Main results expectedJuly 1, 2027
Study endsJanuary 1, 2028
Registry record updatedNovember 2, 2026
Trial IDNCT06392217 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 and older with histologically confirmed breast cancer and imaging-confirmed bone metastases.

Probably not a fit

Patients who are pregnant or lactating, or those with serious concurrent diseases may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the efficacy and safety of incadronate in patients suffering from breast cancer with bone metastases. It involves real-world data collection from participants who meet specific eligibility criteria, including confirmed breast cancer and bone metastases. The study will monitor the outcomes of treatment with incadronate, focusing on both its effectiveness and any potential side effects experienced by the patients.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for breast cancer patients with bone metastases, potentially improving their quality of life and treatment outcomes.

How similar studies have gone: While this study focuses on a specific treatment approach, similar studies evaluating bisphosphonates for bone metastases in breast cancer have shown promising results.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Male or female aged 18 years or above;
2. Can understand the purpose of clinical trials and the benefits and risks, voluntarily participate in and sign the informed consent
3. The physical status score of the Eastern Cooperative Oncology Group (ECOG) was ≤3;
4. Histologically or cytologically confirmed breast cancer;
5. Imaging or histocytology confirmed bone metastases;
6. There were indications of useing Incadronate and no contraindications in the use of Incadronate;
7. New York Heart Association(NYHA)cardiac function grade ≤II, No serious heart disease;
8. All women of childbearing age, fertile men or their spouses did not plan to have children or donate sperm throughout the trial period until 6 months after the last dose, or voluntarily took effective contraceptive measures.

Exclusion Criteria:

1. Pregnant or lactating women;
2. Patients with acute and chronic infections, or with other serious diseases at the same time, were judged not suitable for this study;
3. Other malignant tumors within 5 years (except the following cases: cured skin basal cell carcinoma, cervical carcinoma in situ, thyroid papillary carcinoma; A second primary cancer that has been eradicated and has not recurred within five years; Investigators have identified the primary tumor source of the metastases);
4. Mental illness or mental disorder, poor compliance can not cooperate with and describe treatment response;
5. There are serious organic diseases or major organ failure, such as decompensated heart, lung, liver, kidney failure, which can not tolerate treatment;
6. Patients with bleeding tendency;
7. The researcher believes that the patient has other conditions that are not suitable for participating in this study.

Where it's running

  • Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.